Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Insight Molecular Diagnostics (IMDX) Other Non Operating Income (2020 - 2025)

Insight Molecular Diagnostics (IMDX) has disclosed Other Non Operating Income for 6 consecutive years, with $506000.0 as the latest value for Q4 2025.

  • Quarterly Other Non Operating Income rose 246.58% to $506000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.0 million through Dec 2025, up 118.83% year-over-year, with the annual reading at $1.0 million for FY2025, 118.83% up from the prior year.
  • Other Non Operating Income hit $506000.0 in Q4 2025 for Insight Molecular Diagnostics, up from $223000.0 in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $1.1 million in Q2 2021 to a low of -$371000.0 in Q4 2022.
  • Historically, Other Non Operating Income has averaged $200250.0 across 5 years, with a median of $126000.0 in 2023.
  • Biggest five-year swings in Other Non Operating Income: skyrocketed 28375.0% in 2021 and later plummeted 1900.0% in 2022.
  • Year by year, Other Non Operating Income stood at $1.1 million in 2021, then tumbled by 132.8% to -$371000.0 in 2022, then surged by 156.06% to $208000.0 in 2023, then dropped by 29.81% to $146000.0 in 2024, then skyrocketed by 246.58% to $506000.0 in 2025.
  • Business Quant data shows Other Non Operating Income for IMDX at $506000.0 in Q4 2025, $223000.0 in Q3 2025, and $125000.0 in Q2 2025.